4.8 Article

Superoxide dismutase 1 (SOD1) is a target for a small molecule identified in a screen for inhibitors of the growth of lung adenocarcinoma cell lines

Publisher

NATL ACAD SCIENCES
DOI: 10.1073/pnas.1113554108

Keywords

chemical biology; target discovery and validation; gene interaction network

Funding

  1. National Institutes of Health [PO1 CA129243-03]
  2. National Cancer Institute Cancer Center [P30 CA08748]
  3. Commonwealth Foundation for Cancer Research
  4. Experimental Therapeutics Center of MSKCC
  5. William Randolph Hearst Fund in Experimental Therapeutics
  6. Lillian S. Wells Foundation
  7. Swedish Research Council
  8. Canadian Institutes of Health Research

Ask authors/readers for more resources

We previously described four small molecules that reduced the growth of lung adenocarcinoma cell lines with either epidermal growth factor receptor (EGFR) or KRAS mutations in a high-throughout chemical screen. By combining affinity proteomics and gene expression analysis, we now propose superoxide dismutase 1 (SOD1) as the most likely target of one of these small molecules, referred to as lung cancer screen 1 (LCS-1). siRNAs against SOD1 slowed the growth of LCS-1 sensitive cell lines; conversely, expression of a SOD1 cDNA increased proliferation of H358 cells and reduced sensitivity of these cells to LCS-1. In addition, SOD1 enzymatic activity was inhibited in vitro by LCS-1 and two closely related analogs. These results suggest that SOD1 is an LCS-1-binding protein that may act in concert with mutant proteins, such as EGFR and KRAS, to promote cell growth, providing a therapeutic target for compounds like LCS-1.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available